SCHEMBL7241026

SCHEMBL7241026

CC(=O)Nc1ccc(C2=C3C=CC(=N3)C(c3ccncc3)=C3C=CC(=N3)C(c3ccncc3)=C3C=CC(=N3)C(c3ccncc3)=C3C=CC2=N3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ BRAF P15056 1/20 0.46
▸ HDAC3 O15379 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ KDM4E B2RXH2 4/20 0.45
▸ GAA P10253 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ HPGD P15428 2/20 0.45
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ PRNP P04156 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ NISCH Q9Y2I1 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MAPK10 P53779 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10568742 0.93 SMN1; SMN2 (0.56) TSHRHTTSMN1; SMN2L3MBTL1KDM4E
SCHEMBL7239834 0.86 NPC1 (0.52) HTTSMN1; SMN2L3MBTL1KDM4EGAA
SCHEMBL7252279 0.82 JAK2 (0.58) HTTSMN1; SMN2L3MBTL1HDAC2KDM4E
SCHEMBL1974249 0.81 TDP1 (0.49) HTTSMN1; SMN2L3MBTL1KDM4EGAA
SCHEMBL7265162 0.81 SMN1; SMN2 (0.46) HTTSMN1; SMN2L3MBTL1KDM4EALDH1A1
SCHEMBL9287008 0.80 AAK1 (0.55) HTTSMN1; SMN2HDAC2
SCHEMBL3728246 0.80 SMN1; SMN2 (0.76) TSHRHTTSMN1; SMN2L3MBTL1BRAF
SCHEMBL245938 0.78 MAPT (0.43) SMN1; SMN2KDM4EGAAALDH1A1MAPT
SCHEMBL7241348 0.76 KMT2A (0.45) HTTSMN1; SMN2BRAFKDM4EALDH1A1
SCHEMBL8865142 0.76 NPC1 (0.50) TSHRSMN1; SMN2KDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203888-A1 Chromophores WELLCOME TRUST LIMITED, THE (GB) 2003-10-30 — — US disclosed
US-20030105130-A1 Thiaporphyrin, selenaporphyrin, and carotenoid porphyrin compounds as c-myc and telomerase inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-06-05 — — US disclosed
EP-1294726-A2 IMPROVEMENTS IN AND RELATING TO CHROMOPHORES Catalyst Biomedica Ltd (GB) 2003-03-26 — — EP disclosed
WO-2002000662-A1 IMPROVEMENTS IN AND RELATING TO CHROMOPHORES CATALYST BIOMEDICA LIMITED (GB) 2002-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203888-A1 Chromophores HCCS, PPOX, HMBS TSHR 3036/4885HTT 1256/4885SMN1; SMN2 4747/4885
US-20030105130-A1 Thiaporphyrin, selenaporphyrin, and carotenoid porphyrin compounds as c-myc and telomerase inhibitors MYCBP, MYC, TERF2IP TSHR 1657/4885HTT 370/4885SMN1; SMN2 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback